Role of in vivo imaging in Head and Neck cancer management

Intravital microscopy (IVM) and optical coherency tomography (OCT) are powerful optical imaging tools that allow visualization of dynamic biological activities in living subjects with subcellular resolutions. They have been used in preclinical and clinical cancer imaging, providing insights into the...

Full description

Saved in:
Bibliographic Details
Published inOral oncology Vol. 146; p. 106575
Main Author Mali, Shrikant B
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.11.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Intravital microscopy (IVM) and optical coherency tomography (OCT) are powerful optical imaging tools that allow visualization of dynamic biological activities in living subjects with subcellular resolutions. They have been used in preclinical and clinical cancer imaging, providing insights into the complex physiological, cellular, and molecular behaviors of tumors. They have revolutionized cancer diagnosis and therapies, allowing for real-time observation of biologic processes in vivo, including angiogenesis and immune cell interactions. Recent developments in techniques for observing deep tissues of living animals have improved bioluminescent proteins, fluorescent proteins, fluorescent dyes, and detection technologies like two-photon excitation microscopy. These technologies have become indispensable tools in basic sciences, preclinical research, and modern drug development. In Vivo imaging can detect subcellular signaling or metabolic events in living animals, but depth-dependent signal attenuation limits the depth from which significant data can be obtained. Cancer cell motility and invasion are key features of metastatic tumors, but only a small portion of tumor cells are motile and metastasize due to genetic, epigenetic, and microenvironmental heterogeneities.
Bibliography:content type line 23
SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
ISSN:1368-8375
1879-0593
1879-0593
DOI:10.1016/j.oraloncology.2023.106575